View Financial HealthBioter 配当と自社株買い配当金 基準チェック /06Bioter配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceNew Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceBoard Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.お知らせ • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United KingdomIs New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.決済の安定と成長配当データの取得安定した配当: BIOTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BIOTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Bioter 配当利回り対市場BIOT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BIOT)n/a市場下位25% (GR)2.0%市場トップ25% (GR)5.3%業界平均 (Construction)8.2%アナリスト予想 (BIOT) (最長3年)n/a注目すべき配当: BIOTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BIOTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BIOTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BIOTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YGR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/27 07:04終値2025/05/30 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioter S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).
お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
New Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).
Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...
Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.
お知らせ • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United Kingdom
Is New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.